Investment
Features
FeesSafety
Academy
More
Pluang+

GBank Financial Holdings to release Q3 2026 earnings on Oct 28 with a live call at 2 PM PST

Company Fundamentals
19 Oct 2026
GlobeNewsWire
View Source
Neutral
GBank Financial Holdings to release Q3 2026 earnings on Oct 28 with a live call at 2 PM PST

GBank Financial Holdings Inc. announced it will release its third quarter 2026 financial results on October 28, 2026, at approximately 1:05 p.m. Pacific Time. The company will host a live earnings call at 2:00 p.m. Pacific Time the same day, accessible remotely via the internet. This event allows investors and interested parties to hear directly from the company about its financial performance and outlook. GBank operates nationally with a focus on gaming and SBA lending, serving multiple states with commercial banking services.

GBank Financial Holdings Inc.'s upcoming Q3 2026 earnings call is noted here with Pluang's Financials-sector snapshot as of Oct 20, 2026 04:51 WIB: out of 142 priced US Financials stocks, 41 rose and 100 fell. Among movers, Allstate Corp (ALL) gained 3.41% to USD 247.78 with a typical hold time of 74 days, contrasting with Galaxy Digital Inc. (GLXY) which dropped 3.28% to USD 15.61 and saw a very short typical hold time of 4 days but 100% buy order activity. Carlyle Group Inc. (CG) also rose 3.24% to USD 36.93, held typically for 113 days.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
2 hours ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
2 hours ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
3 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App